Targeting Hh pathway activation in rhabdomyosarcoma using small molecular SMO inhibitors, vismodegib, sonidegib and saridegib, has been demonstrated to inhibit growth in embryonal rhabdomyosarcoma cell lines [103]. This evidence concerns the gene SMO and rhabdomyosarcoma.